Macrophage-targeted killing and vaccines

被引：2

作者：

Guyre, CA ^{[1
]}

Fanger, MW

机构：

[1] Dartmouth Med Sch, Dept Physiol, Lebanon, NH 03756 USA

[2] Dartmouth Med Sch, Dept Microbiol, Lebanon, NH 03756 USA

[3] Medarex Inc, Annandale, NJ 08801 USA

来源：

RESEARCH IN IMMUNOLOGY | 1998年 / 149卷 / 7-8期

关键词：

macrophage; mAb; NK cell; CTL; bispecific molecules; targeted vaccines; review;

D O I：

10.1016/S0923-2494(99)80034-0

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：655 / 660

页数：6

共 17 条

[1] Clinical perspectives of bispecific antibodies in cancer [J].

deGast, GC ;

vandeWinkel, JGJ ;

Bast, BEJEG .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) :121-123

[2]

Deo YM, 1998, J IMMUNOL, V160, P1677

[3] Bispecific-armed, interferon gamma-primed macrophage-mediated phagocytosis of malignant non-Hodgkin's lymphoma [J].

Ely, P ;

Wallace, PK ;

Givan, AL ;

Graziano, RF ;

Guyre, PM ;

Fanger, MW .

BLOOD, 1996, 87 (09) :3813-3821

[4]

Fanger M W, 1994, Immunomethods, V4, P72, DOI 10.1006/immu.1994.1009

[5]

Goldstein J, 1997, J IMMUNOL, V158, P872

[6]

GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477

[7] Targeting tumor cell destruction with CD64-directed bispecific fusion proteins [J].

Graziano, RF ;

Goldstein, J ;

Sundarapandiyan, K ;

Somasundaram, C ;

Keler, T ;

Deo, YM .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 45 (3-4) :124-127

[8]

GRAZIANO RF, 1995, BISPECIFIC ANTIBODIE, P1

[9]

Guyre CA, 1998, IMMUNOL MED, V26, P291

[10]

GUYRE PM, 1989, J IMMUNOL, V143, P1650

← 1 2 →